Hyaluronic acid-CD44 interactions promote BMP4/7-dependent Id1/3 expression in melanoma cells by Wu, Ruo-Lin et al.
1Scientific RepoRts |  (2018) 8:14913  | DOI:10.1038/s41598-018-33337-7
www.nature.com/scientificreports
Hyaluronic acid-CD44 interactions 
promote BMP4/7-dependent Id1/3 
expression in melanoma cells
Ruo-Lin Wu1,3, Georg Sedlmeier1, Lenka Kyjacova1, Anja Schmaus1,2, Julia Philipp1, 
Wilko Thiele1,2, Boyan K. Garvalov  1 & Jonathan P. Sleeman  1,2
BMP4/7-dependent expression of inhibitor of differentiation/DNA binding (Id) proteins 1 and 3 has been 
implicated in tumor progression and poor prognosis of malignant melanoma patients. Hyaluronic acid 
(HA), a pericellular matrix component, supports BMP7 signalling in murine chondrocytes through its 
receptor CD44. However, its role in regulating BMP signalling in melanoma is not clear. In this study 
we found that depletion of endogenously-produced HA by hyaluronidase treatment or by inhibition of 
HA synthesis by 4-methylumbelliferone (4-MU) resulted in reduced BMP4/7-dependent Id1/3 protein 
expression in mouse melanoma B16-F10 and Ret cells. Conversely, exogenous HA treatment increased 
BMP4/7-dependent Id1/3 protein expression. Knockdown of CD44 reduced BMP4/7-dependent Id1/3 
protein expression, and attenuated the ability of exogenous HA to stimulate Id1 and Id3 expression 
in response to BMP. Co-IP experiments demonstrated that CD44 can physically associate with the 
BMP type II receptor (BMPR) ACVR2B. Importantly, we found that coordinate expression of Id1 or Id3 
with HA synthases HAS2, HAS3, and CD44 is associated with reduced overall survival of cutaneous 
melanoma patients. Our results suggest that HA-CD44 interactions with BMPR promote BMP4/7-
dependent Id1/3 protein expression in melanoma, contributing to reduced survival in melanoma 
patients.
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor β (TGF-β) superfamily. They 
signal through specific type I and II serine/threonine receptors, which in turn activate Smad-1/5/8 transcription 
factors. After this activation, Smad proteins form heteromeric complexes with the common-mediator Smad4 
and translocate into the nucleus, where they regulate gene transcription1. The inhibitor of differentiation/DNA 
binding (Id) genes Id1 and Id3 are well-characterized target genes of the BMP signalling pathway1. The four 
members of the Id family (Id1-4) are helix-loop-helix proteins that lack a DNA-binding domain, and act as 
dominant-negative antagonists of basic helix-loop-helix transcription factors by forming inactive heterodimers2. 
Through this activity Id proteins regulate a variety of cellular processes including proliferation, migration, inva-
sion, angiogenesis, maintenance of stem cell properties, and cell differentiation3,4. Moreover, Id1 and Id3 endow 
tumor cells with stemness properties, thereby contributing to cancer initiation in vivo4–8. Id1 and Id3 are closely 
related, have overlapping biological functions, and can partially compensate for each other4,9.
Increased expression of BMPs such as BMP4 and BMP7 correlates with poor prognosis in various cancers10. 
As direct targets of BMP signaling11–13, Id genes are likely to be key mediators of the prognostic effects of BMPs. 
Notably, Id genes such as Id1 and Id3 also correlate with poor prognosis in many cancer types4.
In the context of malignant melanoma, BMP7 expression correlates with poor prognosis14. Increased levels 
of BMP4 and BMP7 also promote cell migration and invasion of human melanoma cells in vitro15. Consistently, 
increased Id1 expression has been correlated with tumor progression and poor prognosis in malignant melanoma 
patients16. Id3 expression has also been shown to promote tumorigenesis in melanoma17. Thus the BMP/Id axis 
contributes to the malignancy of melanoma.
The ability of BMPs to activate their receptors is regulated by a number of extracellular matrix (ECM) com-
ponents1. For example, hyaluronan (HA) is a linear high molecular weight polysaccharide in the ECM that is 
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composed of repeating disaccharides of β-1-3, β-1-4-linked glucuronic acid and N-acetylglucosamine, and 
which has been implicated in the regulation of BMP signalling in chondrocytes18. Three transmembrane syn-
thases (HAS1, HAS2, HAS3) are responsible for HA synthesis, and extrude HA into the pericellular matrix. 
The biological functions of HA are mainly mediated by cell surface receptors, in particular CD4419. CD44 acts 
as a co-receptor for a number of cell surface growth factors and cytokine receptors, and its ability to act as a 
co-receptor can be regulated by HA20. In chondrocytes, CD44 interacts intracellularly with Smad1, and pro-
motes Smad1 and Smad4 phosphorylation and nuclear translocation in response to BMP7 in HA-dependent 
manner18,21.
High levels of CD44 correlate with cancer progression and poor survival in melanoma patients22. Melanoma 
cells produce large amounts of HA during early tumorigenesis, whereas in later stages, HA is largely produced 
by activated tumor-associated stromal fibroblasts23–25. Thus melanoma cells are exposed to both self-produced 
HA and stroma-derived HA during tumor progression. In melanoma, HA has been implicated in promoting cell 
proliferation25,26, adhesion27, motility28,29, invasion, and metastasis30. In the B16-F10 murine melanoma model, 
inhibition of HA synthesis using 4-MU reduced cell adhesion and locomotion31.
Given that the CD44/HA axis promotes BMP signalling in chondrocytes, and the correlation between these 
factors and poor prognosis in melanoma, we hypothesized that HA might promote BMP4/7-dependent Id1/3 
protein expression in melanoma cells in CD44-dependent manner. In this study, we investigated this hypoth-
esis, and found that the CD44/HA axis fosters BMP4/7-dependent Id1/3 protein expression in melanoma cells 
through interactions between CD44 and BMPR. Consistently, coordinate expression of Id1 or Id3 with HAS2, 
HAS3 or CD44 significantly correlated with reduced survival of cutaneous melanoma patients. We therefore con-
clude that the CD44/HA axis can potentiate the ability of BMP4/7 to activate Id1 and Id3 expression in melanoma 
cells, thereby contributing to poor prognosis.
Results
BMP4/7 stimulation induces Id1/3 protein expression in mouse melanoma cells. We have pre-
viously shown that BMP4 and BMP7 both induce Id1/3 protein expression in B16-F10 and Ret cells, with peak 
induction of Id1/3 protein occurring 6 hours after the stimulation32. In further experiments we found that the 
expression of Id1/3 proteins was increased by BMP4/7 stimulation in a dose-dependent manner (Supplementary 
Fig. S1A). We also determined the effect of BMP4 and BMP7 on proliferation of the melanoma cells. As shown in 
Supplementary Fig. S1B, low concentrations of BMP4/7 had no significant effect on cellular proliferation, whereas 
high concentrations showed an inhibitory effect. These data suggest that a low concentration of BMP4/7 (10 ng/
ml) is sufficient to induce the expression of Id1/3 proteins without having a significant inhibitory effect on cell 
proliferation. This concentration was therefore used for subsequent experiments.
Hyaluronidase digestion reduces BMP-dependent Id1/3 protein expression. The presence of HA 
in the pericellular matrix has been shown to foster the BMP7 signaling pathway in chondrocytes18,21,33. We there-
fore investigated whether HA in the pericellular matrix might play a similar role in regulating BMP-induced Id1/
Id3 expression in B16-F10 and Ret melanoma cells. To this end, HA in the pericellular matrix was depleted by 
hyaluronidase (Hyal) treatment. For both cell lines, significantly reduced levels of pericellular HA were detected 
by HABP staining after treatment with exogenous hyaluronidase (Fig. 1A). In subsequent experiments, cells were 
treated with and without hyaluronidase prior to the stimulation with BMP4/7. Hyaluronidase pre-treatment 
reduced Id1/3 protein expression in response to BMP4 and BMP7 in both melanoma cell lines by around 50% 
(Fig. 1B). These results suggest that HA in the pericellular matrix is required for efficient Id1/3 protein expression 
in response to BMP stimulation.
4-methylumbelliferone (4-MU) treatment reduces BMP-dependent Id1/3 protein expres-
sion. To further substantiate the notion that HA promotes BMP4/7-induced Id1/Id3 expression in melanoma 
cells, we treated the cells with 4-MU, a 7-hydroxy-4-methylcoumarin that inhibits HA synthesis by depleting cel-
lular UDP-glucuronic acid and downregulating HA synthase expression34. To exclude the possibility that 4-MU 
affects cell viability or proliferation in these experiments, we first determined whether 4-MU treatment has any 
direct effects on cell numbers. As shown in Fig. 2A, the number of cells decreased in a concentration-dependent 
manner when the concentrations of 4-MU exceeded 0.25 mM and 0.125 mM for B16-F10 and Ret cells, respec-
tively. Importantly, expression of HA synthase (HAS) 2 and 3 was downregulated after the treatment of the cells 
with concentrations of 4-MU that did not reduce cell numbers (Fig. 2B), which corresponded to reduced amounts 
of HA in the pericellular matrix (Fig. 2C). Note that little or no expression of HAS1 was detected in the cells used 
in this study (Supplementary Fig. S2).
To investigate whether inhibition of endogenous HA synthesis influences BMP4/7-induced Id1/3 protein 
expression, cells were stimulated with BMP4/7 with or without pre-treatment with 4-MU. BMP4/7-induced Id1/3 
protein expression was reduced by 4-MU treatment by around 50% (Fig. 2D). These findings suggest that inhibi-
tion of endogenous HA synthesis reduces Id1/3 protein expression in response to BMP stimulation.
Exogenous HA augments BMP-dependent Id1/3 protein expression. HA is produced not only by 
melanoma cells, but also by other cells in their environment such as fibroblasts. To determine whether HA from 
such exogenous sources can also potentiate BMP-dependent Id1/3 protein expression, B16-F10 cells and Ret cells 
were stimulated with BMP4/7 with or without pre-incubation with various concentrations of HA. Pre-incubation 
with HA modestly augmented BMP4/7-induced Id1/3 protein expression when compared to non-treated control 
cells (Fig. 3). These data again indicate that HA can promote BMP4/7-dependent Id1/3 protein expression.
www.nature.com/scientificreports/
3Scientific RepoRts |  (2018) 8:14913  | DOI:10.1038/s41598-018-33337-7
Figure 1. Depletion of HA in the pericellular matrix reduces BMP-dependent Id1/3 protein expression in 
murine melanoma cells. (A) B16-F10 and Ret cells were treated with 100 rTU bovine testis hyaluronidase (Hyal) 
for 90 min or 24 hours. Hyaluronic acid was detected using HABP immunofluorescence staining. HABP staining 
intensity from at least 15 images was quantified using ImageJ in a blinded fashion. Scale bar 50 μm. Student’s 
t-test: ***p < 0.001. (B) B16-F10 and Ret cells were treated or not treated with 100 rTU hyaluronidase for 
90 min or 24 hours, medium was changed, and then stimulated with 10 ng/ml recombinant BMP4/7 for another 
6 hours. Cell lysates were analyzed for Id1/3 protein expression by Western blot. β-actin was used as a loading 
control. Densitometry analysis was performed using ImageJ software. Numbers indicate integrated density 
relative to untreated controls.
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Figure 2. Inhibition of HA synthesis reduces BMP-dependent Id1/3 protein expression in murine melanoma cells. 
(A) B16-F10 and Ret cells were treated with the indicated concentrations of 4-methylumbelliferone (4-MU) for 
48 hours. The number of cells was then quantified on the basis of DNA content using CyQUANT assay. The mean 
and SE of triplicate samples are shown. Data represents means ± SD, n = 3. Student’s t-test: *p < 0.05; n.s., non-
significant. (B) B16-F10 and Ret cells were treated with 0.25 mM (B16-F10) and 0.125 mM (Ret) 4-MU for 48 hours. 
Total RNA was prepared, and RT-PCR was performed to analyze the gene expression of HAS2 and HAS3. For a 
negative control, water instead of cDNA was added to the PCR reaction (H2O). Rplp0 was used as an internal loading 
control. (C) B16-F10 and Ret cells were treated or not treated with the indicated concentrations of 4-MU for 48 hours. 
Hyaluronic acid was detected using HABP immunofluorescence staining. HABP staining intensity was quantified 
using ImageJ. At least 15 images were quantified in a blinded fashion. Scale bar 50 μm. Student’s t-test: *p < 0.05, 
**p < 0.01, ***p < 0.001. (D) B16-F10 and Ret cells were treated or not treated with 4-MU (0.25 mM, B16-F10, right; 
0.125 mM, Ret) for 48 hours, then stimulated with 10 ng/ml recombinant BMP4/7 for another 6 hours. Cell lysates 
were then analyzed for Id1/3 protein expression by Western blot. β-actin was used as a loading control. Densitometric 
quantification is shown below the Western blots, representing the signal normalized to the loading control (β-actin), 
relative to the untreated controls.
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Knockdown of CD44 reduces BMP-dependent Id1/3 protein expression. Next we deter-
mined whether CD44, the principal cell surface receptor for HA, plays a role in the ability of HA to stimulate 
BMP-induced Id1 and Id3 expression in B16-F10 and Ret melanoma cells. Using FACS analysis, surface expres-
sion of CD44 was detected at high levels in both melanoma cell lines (Fig. 4A). Western blot analysis showed that 
virtually all CD44 expressed in the cells is the standard 85 kDa isoform (Supplementary Fig. S3). CD44 expression 
was knocked down using siRNA (Fig. 4A,B). In comparison to scrambled siRNA controls, CD44 knockdown was 
found to reduce Id1/3 expression in response to BMP4 and BMP7 (Fig. 4C). This finding suggests that the interac-
tion between HA and its surface receptor CD44 contributes to BMP-dependent Id1/3 expression. Consistent with 
this notion, knockdown of CD44 abrogated the ability of exogenously added HA to stimulate Id1/3 expression in 
response to BMP, with the exception of Id3 expression in Ret cells following BMP4 treatment (Fig. 4D).
CD44 and the BMP receptor ACVR2B physically interact. Next we used qRT-PCR to determine 
which BMP receptors are expressed on Ret and B16-F10 cells. As shown in Supplementary Fig. S4, both cell 
lines express ALK3 and ACVR2B as the major type I and type II receptors, respectively. To investigate whether 
CD44 can act as a co-receptor for BMP in melanoma cells, co-IP of CD44 and ACVR2B was performed. As 
shown in the left panels of Fig. 5, immunoprecipitation of CD44 resulted in the co-IP of ACVR2B in B16-F10 
and Ret cells. In the right panels of Fig. 5, immunoprecipitation of ACVR2B resulted in the co-IP of CD44 in 
both cell lines. In B16-F10 cells, we observed no co-IP between ACVR2B and CD44 in the absence of HA or 
ligand, while HA and BMP7 both stimulated complex formation between ACVR2B and CD44. In Ret cells, a 
weak association between ACVR2B and CD44 was observed in the absence or presence of HA or BMP7 individ-
ually, which was strongly augmented in the presence of HA and BMP7 together. These data suggest that HA can 
promote BMP4/7-dependent Id1 and Id3 protein expression through promoting the interaction between CD44 
and ACVR2B, with the exact degree of interaction being dependent on the cellular context and the presence or 
absence of ligands.
Coordinate expression of HAS and Id genes in human melanoma correlates with reduced sur-
vival. Our data using cultured cell lines suggest that increased levels of HA could potentially contribute to 
poor prognosis by stimulating Id expression in a CD44/HA-dependent manner. To determine whether these 
findings might have relevance in the context of human melanoma, we analysed mRNA expression data in the 
cancer genome atlas (TCGA) database35,36 derived from cutaneous melanomas, to assess whether coordinate 
expression of Id1 and/or Id3 with HAS genes or CD44 correlates with reduced survival. Coordinate expression of 
Figure 3. Exogenous HA promotes BMP-dependent Id1/3 protein expression in murine melanoma cells. B16-
F10 and Ret cells were treated with the indicated concentrations of HA for 24 hours, then stimulated with 10 ng/
ml recombinant BMP4/7 for another 6 hours. Cell lysates were then analyzed for Id1 and Id3 protein expression 
by Western blot. β-actin was used as loading control. Densitometric quantification is shown below the Western 
blots, representing the signal normalized to the loading control (β-actin), relative to the untreated controls.
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Figure 4. Knockdown of CD44 reduces BMP-dependent Id1/3 protein expression in murine melanoma cells. (A) 
B16-F10 and Ret cells were transfected with CD44 siRNA (siCD44) or scrambled control siRNA (siScr) for 24 hours 
(CD44 siRNA group, yellow histogram; scrambled siRNA group, blue histogram). Cells were incubated with the 
anti-CD44 mAb KM81 and surface expression of CD44 was measured by FACS analysis. Isotype-matched control 
IgG antibody (red and blue histogram) served as a control. (B) Western blot detection of CD44 after the siRNA-
mediated CD44 knockdown (siCD44). Scrambled siRNA (siScr) was used as a control. β-actin was used as a loading 
control. (C) B16-F10 and Ret cells were transfected with CD44 siRNA (siCD44) or scrambled siRNA (siScr) for 
24 hours, then stimulated with 10 ng/ml recombinant BMP4/7 for another 6 hours. Cell lysates were then analyzed 
for Id1/3 protein expression by Western blot. β-actin was used as a loading control. (D) B16-F10 and Ret cells were 
transfected with CD44 siRNA or scrambled siRNA. 24 hours after transfection, cells were incubated with HA for 
24 hours, then stimulated with 10 ng/ml recombinant BMP4/7 for another 6 hours. Cell lysates were then analyzed 
for Id1/3 protein expression by Western blot. β-actin was used as a loading control. Densitometric quantification is 
shown below the Western blots, representing the signal normalized to the loading control (β-actin), relative to the 
untreated controls.
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Id1 and HAS2 as well as Id1 and CD44 both correlated with reduced overall survival (Fig. 6). Similarly coordinate 
expression of Id3 with HAS2, HAS3 or CD44 was also associated with reduced overall survival. Furthermore, 
coordinate expression of Id3 and CD44 correlated with significantly reduced disease-free survival (Fig. 6). These 
data are consistent with the notion that the CD44/HA axis and Id1/Id3 expression have protumorigenic roles in 
human melanoma, resulting in reduced survival.
Discussion
Here we report that HA promotes BMP4/7-dependent Id1/3 protein expression in melanoma cells. Specifically 
we show that degradation of HA in the pericellular matrix or inhibition of endogenous HA synthesis reduces 
BMP4/7- dependent Id1/3 protein expression, while exogenous HA has the opposite effect. CD44, the main cell 
surface receptor for HA, physically interacts with the BMP receptor ACVR2B, and is required for the ability of 
HA to promote BMP-induced Id1/Id3 expression. Coordinate expression of Id1 or Id3 or CD44 with HAS2 or 
HAS3 or CD44 was found to be associated with reduced survival of human melanoma patients. Together these 
findings identify a novel role for HA in the regulation of BMP signaling pathway in melanoma that has prognostic 
significance.
CD44 is as a multi-domain signaling platform that integrates extracellular matrix cues with growth factor and 
cytokines signals20. CD44 exerts a co-receptor function for a variety of receptor tyrosine kinases including Met, 
VEGFR-2, PDGFR, and EGFR through physically interacting with these cell surface proteins in cis, thereby pro-
moting their ligand-dependent activation. Although alternatively spliced CD44 variants often act as co-receptors, 
the CD44s isoform interacts with ErbB2 and ErB3 in Schwann cells, and thereby acts as a co-receptor for neureg-
ulin37, and also acts to stimulate TGF-βRI activation38. Here we show that CD44s also physically interacts with 
the BMP receptor ACVR2B and provide evidence that it acts as a co-receptor for BMPs, as knockdown of CD44 
reduced BMP-dependent Id1/Id3 expression. As the cytoplasmic portion of CD44 interacts with Smad1 in chon-
drocytes, and promotes phosphorylation of Smad1 and Smad4 and their nuclear translocation18,21, it is likely that 
a similar mechanism underlies the BMPR co-receptor function for CD44 in melanoma cells.
We show here that HA promotes BMP4 and BMP7 signaling, as evidenced by increased Id1 and Id3 expres-
sion, in a CD44 dependent manner. A dependence on CD44 for BMP4-induced Id3 expression in Ret cells 
Figure 5. CD44 and ACVR2B can physically interact in melanoma cells. B16-F10 and Ret cells were pre-
incubated with HA (50 µg/ml) for 48 hours, and then stimulated with or without BMP7 (10 ng/ml) for another 
6 hours. Cell lysates were then analyzed for CD44 and ACVR2B protein expression by co-immunoprecipitation 
assays. In each case, the samples in the two left panels were immunoprecipitated with CD44 antibodies, and the 
samples in the right panels were immunoprecipitated with ACVR2B antibodies. The Western blots were probed 
with either CD44 or ACVR2B antibodies as indicated. Isotype control antibodies were used for negative control 
immunoprecipitations. Densitometric quantification is shown below the Western blots, representing the signal 
relative to the input lanes.
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was not observed, suggesting that the activity of other signaling pathways may cross-regulate Id3 expression 
in these cells. In chondrocytes, HA has been shown to potentiate BMP7-induced phosphorylation and nuclear 
localization of Smad1 and Smad418,21. HA can also cross-regulate the co-receptor function of CD44 in other 
Figure 6. Analysis of the TCGA Cutaneous Melanoma datasets (SKCM, provisional) shows that increased 
expression of Id1 or Id3 with HAS or CD44 genes is associated with poor prognosis in cutaneous melanoma 
patients. Kaplan-Meier analysis of overall survival (A–E) and disease-free survival (F) of 479 patients with 
cutaneous melanoma from the TCGA cohort (TCGA, provisional) whose tumors express different levels of Id1 
or Id3 with HAS or CD44 mRNA. A z-score threshold of 2.0 was used to discriminate between tumors with low 
and high (hi) expression of the indicated genes. Survival curves were plotted using the cBio portal35,36.
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context. For example, HA potentiates the ability of CD44s to activate TGF-βRI38. Conversely, HA inhibits 
ligand-induced PDGF β-receptor activation by fostering the formation of a physical complex between CD44s and 
PDGF β -receptor, in which CD44s probably recruits a negatively acting phosphatase to the PDGFβ-receptor39. 
CD44-dependent CXCL12-induced activation of CXCR4 is positively regulated by high molecular weight HA, 
but is negatively regulated by small HA oligosaccharides40. Similarly, high molecular weight HA fosters ErbB2 
phosphorylation in a CD44-dependent manner, while small HA oligosaccharides inhibit ErbB2 phosphoryla-
tion41. Here we show that high molecular weight HA stimulates CD44-dependent BMP-induced expression of 
Id1 and Id3.
Id1 and Id3 proteins are overexpressed in a variety of human cancers, and play critical roles in cancer devel-
opment and progression4. The tumor-promoting properties of these transcriptional regulators, and the ability 
of the HA/CD44 axis to promote their expression in response to BMP stimulation, likely underlies the asso-
ciation between coordinate expression of Id1/Id3 and HAS2/HAS3/CD44, and reduced survival of melanoma 
patients. Increased BMP-induced Id1/Id3 expression in response to HA could act at a number of levels to promote 
melanoma formation and progression. Id1/Id3 expression promotes stemness properties and tumor initiation4. 
Both BMP4 and BMP7 are present in the skin42,43, and the skin is a HA-rich organ44. Thus the augmentation of 
BMP-induced Id1 and Id3 expression by HA may be important for the genesis of melanoma once BMP-mediated 
growth inhibition has been overcome45. In addition, if disseminating melanoma cells settle in an HA-rich 
microenvironment with only low concentrations of BMPs, then melanoma metastasis formation may be fostered 
by HA-stimulated BMP-induced Id1/Id3 expression due to the tumor-initiating properties endowed on cancer 
cells by Id1 and Id3.
In this study, we have focused on melanoma. Nevertheless the mechanism of HA-stimulated BMP-induced 
Id1/Id3 expression may be relevant for other cancers, given that Id expression correlates with poor prognosis for a 
broad range of tumor types4. We have also focused on only one type II BMP receptor, ACVR2B. Future work will 
determine whether the activity of other BMP receptors is also fostered by the HA/CD44 axis.
Id1 and Id3 proteins are considered to have overlapping biological functions, and can compensate for each 
other. Therefore, inhibition of these Id proteins singly might not be sufficient to achieve anticancer effects. Our 
study reports a novel functional link between HA-CD44 interaction and BMP-induced Id1 and Id3 protein in 
melanoma. Targeting Id1 and Id3 protein expression by perturbation of the HA-CD44 interaction might be a 
promising and effective approach for melanoma therapy.
Materials and Methods
Cell culture and BMP stimulation. The murine melanoma cell line B16-F10 was cultured in DMEM 
(Thermo Fisher Scientific, Darmstadt, Germany) supplemented with 10% FCS (Thermo Fisher Scientific, 
Darmstadt, Germany) and 1% penicillin/streptomycin (Thermo Fisher Scientific, Darmstadt, Germany). The 
murine melanoma cell line Ret46 was grown in RPMI (Thermo Fisher Scientific, Darmstadt, Germany) contain-
ing 10% FCS and 1% penicillin/streptomycin. Both cell lines were cultivated at 37 °C in a 5% CO2 atmosphere. 
Stimulation of tumor cells with mouse recombinant BMP4 or BMP7 (R&D Systems, Wiesbaden-Nordenstadt, 
Germany) was performed with the indicated concentrations. Bovine testis hyaluronidase (BTH) and 4-MU 
sodium salt were purchased from Sigma-Aldrich, Taufkirchen, Germany. High molecular weight HA (Healon5) 
was from Abbott Medical Optics (Uppsala, Sweden).
Cell proliferation assay. The CyQuant NF cell proliferation assay kit (Invitrogen, Karlsruhe, Germany) was 
used to assess the effect of mouse recombinant BMP4 or BMP7 or 4-MU on cell proliferation. B16-F10 or Ret cells 
were seeded at a density of 2000–4000 cells/well in a 96-well plate and treated with BMP4 or BMP7 (0–100 ng/
ml) or 4-MU (0–5 mM) for 48 hours or 72 hours. Subsequently, the cells were incubated with 50 µl CyQuant Dye 
Binding Solution at 37 °C for 30 minutes. The fluorescence intensity of each well was measured with excitation at 
480 nm and emission at 530 nm by using a fluorescence Infinite 200 PRO microplate reader (Tecan, Männedorf, 
Switzerland).
HABP staining. Cells were plated on glass coverslips and incubated for 72 hours. BTH treatment was per-
formed 90 min or 24 hours before analysis as indicated, then the medium was changed prior to BMP stimulation. 
Where indicated, cells were treated with the indicated concentrations of 4-MU 48 hours prior to analysis. For 
HABP staining, cells were fixed with 3.7% formaldehyde-PBS, 70% ethanol, and 5% glacial acetic acid (all v/v) for 
15 min at room temperature and subsequently air-dried. Cells were washed three times with PBS. Blocking was 
performed using 3% BSA (biotin-free) in PBS for 1 hour at room temperature. Hyaluronic acid was stained with 
hyaluronic acid binding protein (HABP, Calbiochem #385911, 2.5 µg/ml) in 3% BSA overnight at 4 °C. Cells were 
washed three times with PBS. HABP was detected using Alexa Fluor 546-labelled Streptavidin (5 µg/ml) at room 
temperature for 1 hour. Cells were washed three times with PBS and stained with DAPI (0.5 µg/ml for 5 min). 
Slides were mounted with Fluoromount. Immunofluorescence images were acquired using an Axio Imager D1 
microscope and a 63x objective (Zeiss, Germany). Total HABP staining signal (integrated density) was measured 
in at least 15 randomly selected fields per condition using ImageJ. The mean signal of fields stained with Alexa 
Fluor 546-labelled Streptavidin only (background) was subtracted, and the numbers were normalized to the mean 
value for the untreated cells, which was set to 1.
RNA isolation and Reverse transcription PCR (RT-PCR). Total RNA was isolated from the cells 
using TRIzol (Invitrogen, Karlsruhe, Germany) according to the manufacturer’s instructions. RNA (5 μg) was 
digested by 5 U DNase I (Thermo Fisher Scientific, Darmstadt, Germany) at 37 °C for 30 minutes. DNase I was 
inactivated by adding EDTA and heating at 65 °C for 10 minutes. After precipitation of the RNA with isopro-
panol, cDNA synthesis was performed using RevertAid H Minus reverse transcriptase and random primers 
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(both from Thermo Fisher Scientific, Darmstadt, Germany). Negative controls containing no enzyme were set 
up for each sample. For standard semi-quantitative RT-PCR, cDNA templates were amplified with 30 cycles 
of denaturing at 95 °C for 15 sec, annealing for 30 sec and extension at 72 °C for 1 min. The following primers 
and annealing temperature were used: mouse HAS2, forward: 5′-ACAGGCACCTTACCAACAGGG-3′, reverse: 
5′- GCATGCATAGATCAAAGTTCCCACG-3′ (66 °C); mouse HAS3, forward: 5′- ACTGCCTTCAAGGCC 
CTTGG-3′, reverse: 5′-AATGTTCCAGATGCGGCCAC-3′ (60 °C); mouse CD44, forward 5′-CCCACCATGG 
ACCAAATGA-3′, reverse: 5′-GGTGCTCCGGATAAAGAAGGA-3′ (58 °C); mouse Rplp0, forward: 
5′-GGACCCGAGAAGACCTCCTT-3′, reverse: 5′-GCACATCACTCAGAATTTCAATGG-3′ (60 °C). Amplicons 
were analysed using agarose gel electrophoresis using standard procedures.
Quantitative RT-PCR (qRT-PCR). Equal amounts of cDNA were mixed with SYBR Green PCR Master 
Mix (Thermo Fisher Scientific, Darmstadt, Germany) and 0.5 µM of each primer pair. qRT-PCR was con-
ducted at 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, 55 °C for 1 min, and 72 °C for 1 min using 
the Agilent Mx3005P QPCR System (Agilent, Santa Clara, CA, US). The specificity of the reaction was veri-
fied by analyzing melting curves. The sequences of primers used for qRT-PCR analysis of type I and type II 
BMP receptors are listed below. Rplp0 mRNA transcripts were served as an internal control. Relative quantita-
tive analysis was performed using the ∆∆Ct method. ALK2, forward: 5′-GGCTGCTTTCAGGTTTATGAG-3′, 
reverse: 5′-TACTGCAAACACCACCGAGA-3′; ALK 3, forward: 5′-GGTCCTGCTGTCTCACTGGT-3′, 
reverse: 5′-GCTGTTCGGAGAAATTGGAA-3′; ALK6, forward: 5′-TCCAGAGCTTCGTAAGAGCA-3′, 
reverse 5′-ATTTGGCGCTGAGCTATGAC-3′; BMPR2, forward 5′-CTGCGGCTGCTTCGCAGAAT-3′, reverse: 
5′-TGGTGTTGTGTCAGGAGGTGG-3′. ACVR2A, forward: 5′-TTGGTTCTGTCTCTTTCCCAA-3′, reverse: 
5′-CGTTCGCCGTCTTTCTTATC-3′; ACVR2B, forward: 5′-GAAGATGAGGCCCACGATTA-3′, reverse: 
5′-GGAGGTCACCAGAGAGACGA-3′.
Western blot. Cells were lysed in radioimmunoprecipitation assay buffer (50 mM Tris, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate) supplemented with EDTA-free Protease Inhibitor 
Cocktail (Roche, Mannheim, Germany). After sonication for 20 to 40 seconds at 50/60 Hz to break down chro-
mosomal DNA, the lysates were centrifuged for 15 min at 13000 rpm. Total protein concentration was meas-
ured using the Pierce BCA protein assay kit (Thermo Fisher Scientific, Darmstadt, Germany). Proteins were 
diluted in sample buffer (final concentration: 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.002% bromo-
phenol blue and 62.5 mM Tris-HCI pH 6.8, with 250 mM dithiothreitol added to the sample buffer freshly prior 
to use). The samples were subjected to SDS-PAGE and transferred to Immobilon-P PVDF Membrane (Merck 
Millipore, Darmstadt, Germany) by using standard Western blotting techniques. The membranes were probed 
with anti-human/mouse Id1 (clone 195–14, M086, 1 µg/ml) or Id3 (clone 17-3, M101, 1 µg/ml) rabbit mono-
clonal antibodies (CalBioreagents, California, USA), anti-ACTR II (F-12, sc-390977, 1 µg/ml, Santa Cruz 
Biotechnology, California, USA), and anti-CD44 (KM81, 1 µg/ml, hybridoma obtained from ATCC). The mono-
clonal anti-β-actin antibody (clone AC-15, #A5441, Sigma Aldrich, Taufkirchen, Germany) was used for a load-
ing control. HRP-conjugated secondary antibodies were from DAKO (Hamburg, Germany). The protein bands 
were visualized using the Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, Darmstadt, Germany) 
for β-actin. AceGlow Chemiluminescence Substrate (Peqlab, Erlangen, Germany) was used to detect Id1 and 
Id3 proteins. Densitometry analysis was carried out using ImageJ. Numbers represent background-subtracted 
integrated densities of Id1, Id3, and CD44 divided by corresponding background-subtracted integrated densities 
of loading control (β-actin) bands. The numbers were normalized to lane 1 (control), which was set as 100%. In 
case of IP experiments, numbers represent background-subtracted integrated densities of CD44 and ACVR2B, 
normalized to lane 1. Three independent experiments were conducted and representative results are shown.
siRNA-mediated CD44 knockdown. CD44 small interfering RNA (siCD44) and scrambled siRNA (siScr) 
were purchased from Thermo Fisher Scientific (ID: s63661), Darmstadt, Germany, and Origene (ID: siRNA-27), 
Herford, Germany, respectively. Transfections were performed with Lipofectamine 2000 (Invitrogen, Karlsruhe, 
Germany) according to the manufacturer’s instructions. Total RNA was isolated for detecting transcription of 
CD44 24 hours after transfection with CD44 siRNA, and flow cytometry together with western blot analysis were 
performed at this time point to analyse surface and total expression of CD44 protein, respectively. The transfec-
tion efficiency was monitored using an expression plasmid for Green Fluorescent Protein (GFP) through fluores-
cence microscopy and flow cytometry (Supplementary Fig. S5).
Flow cytometry. Cells were detached with Ca2+/Mg2+ (-) DPBS and washed twice with Ca2+/Mg2+ (-) DPBS 
containing 10% FCS. The cells were resuspended with Ca2+/Mg2+ (-) DPBS containing 10% FCS. The cells were 
then incubated with the rat anti-mouse CD44 monoclonal antibody (KM81, 5 µg/ml, hybridoma obtained from 
ATCC) or isotype-matched control rat IgG (MAB006, 5 µg/ml, BD Biosciences, Heidelberg, Germany) for 1 hour 
at 4 °C, then were incubated with the secondary antibody for 30 minutes after three washes with PBS. Finally, 
FACS measurements were performed with the single cell suspension after washing a further three times with PBS. 
FACS analysis was performed using a FACSCanto II (BD Biosciences, Heidelberg, Germany) to determine GFP 
or CD44 expression. Dead cells were excluded using SytoxRed (Invitrogen, Karlsruhe, Germany). Unstained cells 
and cells incubated only with isotype control or secondary antibody were used as a negative control.
Co-immunoprecipitation. B16-F10 and Ret cells were incubated with HA and/or BMPs as indicated. Cells 
were lysed in 30 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5% Triton-X-100, and 0.5% sodium deoxycholate. 
Cell lysates were placed on ice for 20 minutes, briefly sonicated, then centrifuged at 13000 g at 4 °C for 20 min-
utes. Pre-clearing was performed by incubating the cell lysates with Protein G-sepharose beads (Merckmillipore, 
Darmstadt, Germany), followed by centrifugation to remove the beads. The PureProteome Protein A/G Mix 
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Magnetic Bead suspension (Merckmillipore, Darmstadt, Germany) was first incubated with an anti-ACVR2 poly-
clonal antibody (H-65, sc-25451, 0.5 µg/ml, Santa Cruz Biotechnology, CA, USA), with an anti-CD44 monoclonal 
antibody (clone IM7, #550538, 0.25 µg/ml, BD Biosciences, Heidelberg, Germany), or with an isotype-matched 
control IgG at room temperature for 30 minutes. The magnetic beads were then mixed with a 250 µl volume 
of 5 mM bis (sulfosuccinimdyl) suberate crosslinker solution at room temperature for 30–60 minutes. The 
pre-cleared cell lysates were then incubated with the magnetic beads at 4 °C overnight. Magnetic beads were 
separated from the lysate using a magnetic field, and washed four times with PBS. The magnetic beads were 
finally resuspended in 50 µl sample buffer and heated at 70 °C for 10 minutes. The supernatant was subjected to 
SDS-PAGE and Western blotting.
Statistical analyses. Comparison between two groups in the proliferation assay and quantification of HABP 
stainings was performed using the Student’s t-test. Statistical significance was set at p < 0.05.
Data Availability Statement
Materials, data and associated protocols will be made promptly available to interested readers without undue 
qualifications in material transfer agreements.
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